Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Licenses CFTR Next-Generation Sequencing Assay From Baylor Genetics for Use With the Juno System
SOUTH SAN FRANCISCO, Calif., Aug. 17, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and Baylor Genetics today announced that they have entered into a licensing agreement to offer a next-generation sequencing (NGS) library prep assay that enables efficient sequencing of the CFTR
View HTML
Toggle Summary Fluidigm Announces Sale of $30 Million of Common Stock in At-The-Market Equity Offering
SOUTH SAN FRANCISCO, Calif. , Aug. 10, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the sale of 9,090,909 shares of its common stock for aggregate gross proceeds of approximately $30.0 million before commissions and offering expenses under its previously announced
View HTML
Toggle Summary Fluidigm Announces Second Quarter Financial Results and Operational Progress
SOUTH SAN FRANCISCO, Calif. , Aug. 03, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced financial results for the second quarter ended June 30, 2017 . Total revenue for the second quarter was $23.9 million , a decrease of 15% from $28.2 million in the second quarter of
View HTML
Toggle Summary Fluidigm Corporation Announces Termination of Tax Benefit Preservation Plan
SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) announced today that its tax benefit preservation plan had expired pursuant to its terms, effectively terminating the plan as of August 1, 2017 . Stockholders are not required to take any action as a
View HTML
Toggle Summary Fluidigm and Ascendas Genomics Announce Strategic Partnership to Develop Microfluidic Molecular Diagnostics in China
SOUTH SAN FRANCISCO, Calif. and ZHONGSHAN , China , July 27, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) and Ascendas Genomics today announced a strategic partnership to develop molecular diagnostics in China . Under the terms of the partnership, Ascendas Genomics will develop and
View HTML
Toggle Summary Fluidigm to Report Q2 2017 Financial Results and Host Conference Call
SOUTH SAN FRANCISCO, Calif. , July 20, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that it will report second quarter 2017 financial results on Thursday, August 3, 2017 , after the financial markets close. Chris Linthwaite , President and CEO, and Vikram Jog , Chief
View HTML
Toggle Summary Fluidigm Introduces Immuno-Oncology Gene Expression Assay for Translational and Clinical Research
Advanta Immuno-Oncology Gene Expression Assay enables efficient screening of 170 highly informative genes involved in human checkpoint therapeutic response
View HTML
Toggle Summary European Mass Cytometry Consortium Brings CyTOF Technology to Leading Universities to Advance Clinical Research
SOUTH SAN FRANCISCO, Calif. , May 04, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that leading research institutions in the UK have partnered to acquire and implement seven Helios™ mass cytometry systems to empower life-changing discoveries in human health.
View HTML
Toggle Summary Fluidigm Announces First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif. , May 04, 2017 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced its financial results for the first quarter ended March 31, 2017 .  Total revenue for the quarter was $25.5 million , a decrease of 12% from $29.0 million in the first quarter of 2016
View HTML
Toggle Summary Fluidigm To Report Q1 2017 Financial Results And Host Conference Call
SOUTH SAN FRANCISCO, Calif., April 20, 2017 — Fluidigm Corporation (NASDAQ:FLDM) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017, after the financial markets close.   Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host
View HTML